Cooley Advised Chimagen Biosciences on Agreement to Sell Asset to GSK for Up to $750 Million
September 16, 2026
September 16, 2026
PALO ALTO, California, Sept. 16 -- Cooley, a law firm, issued the following news release:
* * *
Cooley advised Chimagen Biosciences on Agreement to Sell Asset to GSK for Up to $750 Million
Cooley advised Chimagen Biosciences, a privately held biotechnology company, on the agreement to sell a potential best-in-class trispecific T cell-engager (TCE) to GSK. Under the terms of the agreement, GSK will pay an upfront fee to acquire full global rights to the TCE . . .
* * *
Cooley advised Chimagen Biosciences on Agreement to Sell Asset to GSK for Up to $750 Million
Cooley advised Chimagen Biosciences, a privately held biotechnology company, on the agreement to sell a potential best-in-class trispecific T cell-engager (TCE) to GSK. Under the terms of the agreement, GSK will pay an upfront fee to acquire full global rights to the TCE . . .